Peak Bio, Inc.

Ignyte Acquisition Corp (Nasdaq: IGNY) was a blank-check company that completed its initial public offering in 2021, targeting the life sciences and biopharmaceutical sector. The SPAC closed its business combination with Peak Bio, Inc., a clinical-stage biopharmaceutical company focused on developing novel antibody therapeutics and antibody-drug conjugate candidates. On October 28, 2022, the combined entity filed an amended current report on Form 8-K/A with the SEC, reflecting updated disclosures tied to the completed de-SPAC transaction. The combined company has since operated under the Peak Bio name following the merger's close. Investors and analysts tracking biopharma SPAC activity can access full filing histories, sponsor profiles, and transaction timelines for IGNY and hundreds of other SPACs by signing up on SpacDesk.